Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05677867 · ClinicalTrials.gov registry record · Phase 1

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

A Phase 1 study of Obesity and Overweight, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT05677867 is a Phase 1 study of Obesity and Overweight that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05677867, a Phase 1 study of Obesity and Overweight, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese. All study participants will receive a total of 2 single doses of this study medication in either form. Form A consists of a PF-07081532 20 mg immediate release tablet and a PF-07081532 60 mg immediate release tablet. Form B consists of a PF-07081532 80 mg immediate release tablet. Each single dose will be separated by a minimum of 6 days. The amount of PF-07081532 in the blood for 4 days after taking each single dose will be compared between the two different formulations of PF-07081532. The total time that participants will take part in this study is about 70 days. The first visit is a screening visit to ensure that participants are appropriately qualified for the study. This will occur up to 28 days before the first single dose. Participants will be admitted into the clinic one day prior to the first single dose and will remain in the clinic for a total of 11 days. The study team will phone the participants 28 to 35 days after the last dose of study medication.

Conditions Studied

Obesity Overweight

Interventions

  • DRUG Formulation A (PF-07081532 20 mg plus 60 mg)
  • DRUG Formulation B (PF-07081532 80 mg)

Study Locations (1)

Connecticut

  • New Haven Clinical Research Unit - New Haven

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-01-18
Est. Completion 2023-03-14
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05677867

The ClinicalTrials.gov registry entry for NCT05677867 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Formulation A (PF-07081532 20 mg plus 60 mg) is the first listed.

NCT05677867 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05677867 about?

NCT05677867 is a clinical study titled "A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese". The purpose of this study is to compare the amount of PF-07081532 in blood after taking two different forms of PF-07081532. This study is seeking participants who are at least 18 years of age and are overweight and/or obese. All study participants will receive a total of 2 single doses of this study...

What is the current status of trial NCT05677867?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-01-18. Estimated completion is 2023-03-14.

What conditions does trial NCT05677867 study?

This clinical trial studies the following conditions: Obesity, Overweight.

What interventions are being tested in trial NCT05677867?

The interventions under investigation include: Formulation A (PF-07081532 20 mg plus 60 mg) (DRUG), Formulation B (PF-07081532 80 mg) (DRUG).

Who is sponsoring clinical trial NCT05677867?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05677867 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.